Statement by the Board of Directors of Nuevolution in relation to the public offer from Amgen
The Board of Directors of Nuevolution unanimously recommends the shareholders of Nuevolution to accept the public offer from Amgen of SEK 32.50 in cash per share. This statement is made by the Board of Directors[1] %20Statement%20by%20the%20Board%20of%20Directors.docx#_ftn1) of Nuevolution AB (publ) (the “Company” or “Nuevolution”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the “Takeover Rules”). Comment from Stig Løkke Pedersen, Chairman of the Board of Directors of Nuevolution “